Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer patients harbouring the same BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to this drug. To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition. We report that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAF(V600E) inhibition. We find in multiple BRAF(V600E) mutant colon cancers that inhibition of EGFR by the antibody drug cetuximab or the small-molecule drugs gefitinib or erlotinib is strongly synergistic with BRAF(V600E) inhibition, both in vitro and in vivo. Mechanistically, we find that BRAF(V600E) inhibition causes a rapid feedback activation of EGFR, which supports continued proliferation in the presence of BRAF(V600E) inhibition. Melanoma cells express low levels of EGFR and are therefore not subject to this feedback activation. Consistent with this, we find that ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032. Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibition in BRAFV600 mutant cancers leads to loss of negative feedback signals regulated by the MAPK pathway, leading to receptor tyrosine kinase (RTK)-mediated reactivation of MAPK signaling through wild type RAS and RAF, particularly in specific tumor types, such as colorectal cancer (9–12).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This finding is consistent with prior studies identifying HER family and FGFR signaling as key mediators of adaptive feedback to RAS-MAPK pathway inhibitors (10–14,21,22) and recent functional genomic screens(40).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [159]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“Figure 1e shows that inhibition of EGFR does not significantly affect proliferation of EGFR in WiDr cells, consistent with the clinical observations that KRAS or BRAF mutant CRC cells do not respond to EGFR-targeted monoclonal antibodie”
ResultEpidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,707
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
Self-citationThe Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Cited by
Items 101–200 of 1,012
Tissue-specific tumorigenesis: context matters
Schneider, G., Schmidt-Supprian, M., Rad, R., & Saur, D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.5 · Cited by 311
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
The NF1 somatic mutational landscape in sporadic human cancers
Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N., & Upadhyaya, M. (2017) · Human Genomics · doi:10.1186/s40246-017-0109-3 · Cited by 303
SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models
Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Geer, M. J., Araki, K., Ozerdem, U., Simeone, D. M., Miller, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0444 · Cited by 315
Use of mutation profiles to refine the classification of endometrial carcinomas
McConechy, M. K., Ding, J., Cheang, M. C., Wiegand, K. C., Senz, J., Tone, A. A., Yang, W., Prentice, L. M., Tse, K., Zeng, T., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4056 · Cited by 301
Implementing personalized cancer genomics in clinical trials
Simon, R., & Roychowdhury, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3979 · Cited by 301
Current status and perspectives of patient-derived xenograft models in cancer research
Lai, Y., Wei, X., Lin, S., Qin, L., Cheng, L., & Li, P. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0470-7 · Cited by 295
BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives
Sanz-Garcia, E., Argiles, G., Elez, E., & Tabernero, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx401 · Cited by 302
Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.045 · Cited by 304
“Each of these knockdown vectors has a unique DNA-based molecular bar code identifier, which allows quantification of the relative abundance of each of the shRNA vectors in the presence and absence of drug (Prahallad et al., 2012).”
BackgroundMethodInfluentialSelf-citationDriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer
Bashashati, A., Haffari, G., Ding, J., Ha, G., Lui, K., Rosner, J., Huntsman, D. G., Caldas, C., Aparicio, S. A., & Shah, S. P. (2012) · Genome Biology · doi:10.1186/gb-2012-13-12-r124 · Cited by 302
Letai, A., Bhola, P., & Welm, A. L. (2022) · Cancer Cell · doi:10.1016/j.ccell.2021.12.004 · Cited by 281
Molecularly targeted cancer therapy: some lessons from the past decade
Huang, M., Shen, A., Ding, J., & Geng, M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.004 · Cited by 291
Valeri, N., Braconi, C., Gasparini, P., Murgia, C., Lampis, A., Paulus-Hock, V., Hart, J. R., Ueno, L., Grivennikov, S. I., Lovat, F., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.006 · Cited by 286
Mao, M., Tian, F., Mariadason, J. M., Tsao, C. C., Lemos, R., Dayyani, F., Gopal, Y. N. V., Jiang, Z.-Q., Wistuba, I. I., Tang, X. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1446 · Cited by 290
“BRAF inhibition resistance has been shown to be mediated, in part, by EGF receptor (EGFR) in 2 recent publications, showing the importance of studies in CRC models (17, 18).”
InfluentialTumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics
Goodspeed, A., Heiser, L. M., Gray, J. W., & Costello, J. C. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0189 · Cited by 276
Cancer heterogeneity—a multifaceted view
Melo, F. D. S. E., Vermeulen, L., Fessler, E., & Medema, J. P. (2013) · EMBO reports · doi:10.1038/embor.2013.92 · Cited by 287
Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
Redig, A. J., & Jänne, P. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.8433 · Cited by 278
Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions
Zarour, L. R., Anand, S., Billingsley, K. G., Bisson, W. H., Cercek, A., Clarke, M. F., Coussens, L. M., Gast, C. E., Geltzeiler, C. B., Hansen, L., et al. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.01.006 · Cited by 274
Renfro, L. A., & Sargent, D. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw413 · Cited by 271
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
Yaeger, R., Cercek, A., O'Reilly, E. M., Reidy, D. L., Kemeny, N., Wolinsky, T., Capanu, M., Gollub, M. J., Rosen, N., Berger, M. F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2779 · Cited by 276
Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP / TAZ activation
Kim, M. H., Kim, J., Hong, H., Lee, S., Lee, J., Jung, E., & Kim, J. (2016) · The EMBO Journal · doi:10.15252/embj.201592081 · Cited by 265
Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
Koncina, E., Haan, S., Rauh, S., & Letellier, E. (2020) · Cancers · doi:10.3390/cancers12020319 · Cited by 259
Schlicker, A., Beran, G., Chresta, C. M., McWalter, G., Pritchard, A., Weston, S., Runswick, S., Davenport, S., Heathcote, K., Castro, D. A., et al. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-66 · Cited by 256
Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
Niederst, M. J., & Engelman, J. A. (2013) · Science Signaling · doi:10.1126/scisignal.2004652 · Cited by 263
The kinome 'at large' in cancer
Fleuren, E. D. G., Zhang, L., Wu, J., & Daly, R. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.18 · Cited by 264
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Pagliarini, R., Shao, W., & Sellers, W. R. (2015) · EMBO reports · doi:10.15252/embr.201439949 · Cited by 253
Misale, S., Arena, S., Lamba, S., Siravegna, G., Lallo, A., Hobor, S., Russo, M., Buscarino, M., Lazzari, L., Sartore-Bianchi, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007947 · Cited by 263
Self-citationDeterminants of metastatic competency in colorectal cancer
Tauriello, D. V. F., Calon, A., Lonardo, E., & Batlle, E. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12018 · Cited by 258
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Targeting Oncogenic BRAF: Past, Present, and Future
Zaman, A., Wu, W., & Bivona, T. G. (2019) · Cancers · doi:10.3390/cancers11081197 · Cited by 245
The Role of EREG/EGFR Pathway in Tumor Progression
Cheng, W.-L., Feng, P.-H., Lee, K.-Y., Chen, K.-Y., Sun, W.-L., Van Hiep, N., Luo, C.-S., & Wu, S.-M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312828 · Cited by 239
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
Precision oncology in metastatic colorectal cancer — from biology to medicine
Di Nicolantonio, F., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 239
Self-citationMelanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Abel, E. V., Basile, K. J., Kugel, C. H., Witkiewicz, A. K., Le, K., Amaravadi, R. K., Karakousis, G. C., Xu, X., Xu, W., Schuchter, L. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65780 · Cited by 244
“A recent study attributed resistance to PLX4032 in mutant BRAF colorectal cancer cells to enhanced EGFR phosphorylation (47).”
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, D., Xue, J. Y., & Lito, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.044 · Cited by 239
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
Gonzalez de Castro, D., Clarke, P. A., Al-Lazikani, B., & Workman, P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.237 · Cited by 239
Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism
Zhao, C., Li, H., Lin, H.-J., Yang, S., Lin, J., & Liang, G. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.001 · Cited by 237
PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective
Cooper, L. A., Demicco, E. G., Saltz, J. H., Powell, R. T., Rao, A., & Lazar, A. J. (2018) · The Journal of Pathology · doi:10.1002/path.5028 · Cited by 228
van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0795 · Cited by 232
“The synergistic activity of dual inhibition of BRAF, EGFR, or PI3K has been reported in preclinical studies, and preliminary preclinical activity has also been reported for triple inhibition (12–14, 18, 19).”
InfluentialStratikopoulos, E. E., Dendy, M., Szabolcs, M., Khaykin, A. J., Lefebvre, C., Zhou, M.-M., & Parsons, R. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.05.006 · Cited by 232
“RAF inhibitors can only transiently inhibit the ERK pathway as they de-repress transcription of HER3 in thyroid tumor cells (Montero-Conde et al., 2013) and EGFR in BRAF (V600E) mutant colon tumor cells (Prahallad et al., 2012).”
BackgroundSafaee Ardekani, G., Jafarnejad, S. M., Tan, L., Saeedi, A., & Li, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047054 · Cited by 224
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Barras, D., Missiaglia, E., Wirapati, P., Sieber, O. M., Jorissen, R. N., Love, C., Molloy, P. L., Jones, I. T., McLaughlin, S., Gibbs, P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0140 · Cited by 230
Boshuizen, J., Koopman, L. A., Krijgsman, O., Shahrabi, A., van den Heuvel, E. G., Ligtenberg, M. A., Vredevoogd, D. W., Kemper, K., Kuilman, T., Song, J.-Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4472 · Cited by 229
Rowland, A., Dias, M. M., Wiese, M. D., Kichenadasse, G., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.325 · Cited by 229
Recent Therapeutic Advances in the Treatment of Colorectal Cancer
Ciombor, K. K., Wu, C., & Goldberg, R. M. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051513-102539 · Cited by 215
Van Cutsem, E., Huijberts, S., Grothey, A., Yaeger, R., Cuyle, P.-J., Elez, E., Fakih, M., Montagut, C., Peeters, M., Yoshino, T., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02459 · Cited by 224
“19,39 Although the mechanisms underlying the outcomes associated with encorafenib and binimetinib combined with cetuximab remain to be fully characterized, preclinical data suggest that encorafenib has target binding characteristics that differ from both vemurafenib and dabrafenib, with a prolonged…”
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Flaherty, K. T., Gray, R., Chen, A., Li, S., Patton, D., Hamilton, S. R., Williams, P. M., Mitchell, E. P., Iafrate, A. J., Sklar, J., et al. (2020) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz245 · Cited by 224
“Patients were excluded from eligibility to subprotocols if they had a tumor histology in which the drug was approved or in late clinical trial or was known not to be of benefit (4,14).”
BackgroundThe coming decade in precision oncology: six riddles
Wahida, A., Buschhorn, L., Fröhling, S., Jost, P. J., Schneeweiss, A., Lichter, P., & Kurzrock, R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00529-3 · Cited by 205
Drug resistance to targeted therapies: Déjà vu all over again
Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 209
Self-citationPIK3CA in cancer: The past 30 years
Arafeh, R., & Samuels, Y. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.002 · Cited by 216
Grothey, A., Fakih, M., & Tabernero, J. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.206 · Cited by 220
KRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
Rational Cancer Treatment Combinations: An Urgent Clinical Need
Boshuizen, J., & Peeper, D. S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.031 · Cited by 210
Small-molecule modulation of Ras signaling
Spiegel, J., Cromm, P. M., Zimmermann, G., Grossmann, T. N., & Waldmann, H. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1560 · Cited by 214
Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance
Wu, J., & Lin, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315056 · Cited by 199
Hong, D. S., Morris, V. K., El Osta, B., Sorokin, A. V., Janku, F., Fu, S., Overman, M. J., Piha-Paul, S., Subbiah, V., Kee, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0050 · Cited by 219
Clarke, C. N., & Kopetz, S. (2015) · PubMed · doi:10.3978/j.issn.2078-6891.2015.077 · Cited by 207
Rad, R., Cadiñanos, J., Rad, L., Varela, I., Strong, A., Kriegl, L., Constantino-Casas, F., Eser, S., Hieber, M., Seidler, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.014 · Cited by 216
“BRAF mutations affect a large variety of cancers; however, response rates to Braf inhibitors differ significantly, ranging from 80% in melanoma to less than 10% in BRAF mutant CRC (Prahallad et al., 2012).”
BackgroundIdentifying chemogenetic interactions from CRISPR screens with drugZ
Colic, M., Wang, G., Zimmermann, M., Mascall, K., McLaughlin, M., Bertolet, L., Lenoir, W. F., Moffat, J., Angers, S., Durocher, D., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0665-3 · Cited by 219
Ahmed, T. A., Adamopoulos, C., Karoulia, Z., Wu, X., Sachidanandam, R., Aaronson, S. A., & Poulikakos, P. I. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.013 · Cited by 214
“Activation of RTK signaling has been found to drive adaptive resistance in various ERK-dependent tumor contexts, including BRAF(V600E) melanoma, colorectal and thyroid cancers, and TNBC and RAS mutant tumors (Chandarlapaty, 2012; Corcoran et al., 2012; Duncan et al., 2012; Karoulia et al., 2016, 2017; Lito et al., 201…”
Synthetic Lethality in Cancer Therapeutics: The Next Generation
Setton, J., Zinda, M., Riaz, N., Durocher, D., Zimmermann, M., Koehler, M., Reis-Filho, J. S., & Powell, S. N. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1503 · Cited by 206
Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Song, Y., Bi, Z., Liu, Y., Qin, F., Wei, Y., & Wei, X. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.006 · Cited by 212
Young, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211
“Several recent studies demonstrate that targeted inhibition of a single oncogenic pathway results in the feedback activation of compensatory pathways, thereby limiting the efficacy of monotherapy (33, 34, 41-45).”
Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography
Tan, D. S. W., Mok, T. S. K., & Rebbeck, T. R. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0096 · Cited by 202
Shah, N., Wang, P., Wongvipat, J., Karthaus, W. R., Abida, W., Armenia, J., Rockowitz, S., Drier, Y., Bernstein, B. E., Long, H. W., et al. (2017) · eLife · doi:10.7554/elife.27861 · Cited by 201
Karoulia, Z., Wu, Y., Ahmed, T. A., Xin, Q., Bollard, J., Krepler, C., Wu, X., Zhang, C., Bollag, G., Herlyn, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.024 · Cited by 205
“…mutant-BRAF, compared to αC-OUT inhibitors. αC-IN inhibitors show increased activity in colorectal and thyroid BRAFV600E tumor cells Colorectal and thyroid BRAFV600E tumors are resistant to first generation RAF inhibitors (Corcoran et al., 2012; Montero-Conde et al., 2013; Prahallad et al., 2012).”
InfluentialColorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes
Linnekamp, J. F., Wang, X., Medema, J. P., & Vermeulen, L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2240 · Cited by 202
Targeting the RB-E2F pathway in breast cancer
Johnson, J., Thijssen, B., McDermott, U., Garnett, M., Wessels, L. F. A., & Bernards, R. (2016) · Oncogene · doi:10.1038/onc.2016.32 · Cited by 199
Self-citationParadoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma
Gibney, G. T., Messina, J. L., Fedorenko, I. V., Sondak, V. K., & Smalley, K. S. M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.83 · Cited by 197
Caruso, S., Calatayud, A.-L., Pilet, J., La Bella, T., Rekik, S., Imbeaud, S., Letouzé, E., Meunier, L., Bayard, Q., Rohr-Udilova, N., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.001 · Cited by 186
Inhibitory feedback control of NF-κB signalling in health and disease
Prescott, J. A., Mitchell, J. P., & Cook, S. J. (2021) · Biochemical Journal · doi:10.1042/bcj20210139 · Cited by 187
Acquired and intrinsic resistance in cancer immunotherapy
Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197
Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities
Wang, W., Kandimalla, R., Huang, H., Zhu, L., Li, Y., Gao, F., Goel, A., & Wang, X. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.002 · Cited by 187
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
Loupakis, F., Cremolini, C., Salvatore, L., Masi, G., Sensi, E., Schirripa, M., Michelucci, A., Pfanner, E., Brunetti, I., Lupi, C., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.024 · Cited by 186
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189
“Colon cancer BRAF Vemurafenib VACO432, SNUC5, HT29, KM20, WiDr; xenografts EGFR-mediated feedback activation EGFR (cetuximab, gefitinib, or erlotinib) [95]”
BackgroundTargeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Gautschi, O., Milia, J., Cabarrou, B., Bluthgen, M.-V., Besse, B., Smit, E. F., Wolf, J., Peters, S., Früh, M., Koeberle, D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000625 · Cited by 186
Robinson, G. W., Orr, B. A., & Gajjar, A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-258 · Cited by 184
A framework for understanding and targeting residual disease in oncogene-driven solid cancers
Bivona, T. G., & Doebele, R. C. (2016) · Nature Medicine · doi:10.1038/nm.4091 · Cited by 181
BRAF V600E mutation-specific antibody: A review
Ritterhouse, L. L., & Barletta, J. A. (2015) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2015.02.010 · Cited by 172
Ma, J., Fong, S. H., Luo, Y., Bakkenist, C. J., Shen, J. P., Mourragui, S., Wessels, L. F. A., Hafner, M., Sharan, R., Peng, J., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00169-2 · Cited by 180
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 180
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine
Ogino, S., Fuchs, C. S., & Giovannucci, E. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.46 · Cited by 177
A framework for identification of actionable cancer genome dependencies in small cell lung cancer
Sos, M. L., Dietlein, F., Peifer, M., Schöttle, J., Balke-Want, H., Müller, C., Koker, M., Richters, A., Heynck, S., Malchers, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207310109 · Cited by 179
Decker, B., Parker, H. G., Dhawan, D., Kwon, E. M., Karlins, E., Davis, B. W., Ramos-Vara, J. A., Bonney, P. L., McNiel, E. A., Knapp, D. W., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0689 · Cited by 174
KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy
Ryan, M. B., Coker, O., Sorokin, A., Fella, K., Barnes, H., Wong, E., Kanikarla, P., Gao, F., Zhang, Y., Zhou, L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110993 · Cited by 177
“In BRAFV600E CRC, EGFR combinations demonstrate efficacy in overcoming resistance to BRAF inhibitors in a preclinical setting and in the clinic (Corcoran et al., 2012; Prahallad et al., 2012; Tabernero et al., 2021).”
BackgroundPencheva, N., Buss, C. G., Posada, J., Merghoub, T., & Tavazoie, S. F. (2014) · Cell · doi:10.1016/j.cell.2014.01.038 · Cited by 175
Tissue-specificity in cancer: The rule, not the exception
Haigis, K. M., Cichowski, K., & Elledge, S. J. (2019) · Science · doi:10.1126/science.aaw3472 · Cited by 172
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Xue, Y., Martelotto, L., Baslan, T., Vides, A., Solomon, M., Mai, T. T., Chaudhary, N., Riely, G. J., Li, B. T., Scott, K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4369 · Cited by 174
The Developing Story of Predictive Biomarkers in Colorectal Cancer
Boussios, S., Ozturk, M., Moschetta, M., Karathanasi, A., Zakynthinakis-Kyriakou, N., Katsanos, K., Christodoulou, D., & Pavlidis, N. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010012 · Cited by 168
Methods and biomarkers for early detection, prediction, and diagnosis of colorectal cancer
Zhang, Y., Wang, Y., Zhang, B., Li, P., & Zhao, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114786 · Cited by 190
BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights
Caputo, F., Santini, C., Bardasi, C., Cerma, K., Casadei-Gardini, A., Spallanzani, A., Andrikou, K., Cascinu, S., & Gelsomino, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215369 · Cited by 162
Stable RNA interference rules for silencing
Fellmann, C., & Lowe, S. W. (2014) · Nature Cell Biology · doi:10.1038/ncb2895 · Cited by 163
Lavallée, V.-P., Baccelli, I., Krosl, J., Wilhelm, B., Barabé, F., Gendron, P., Boucher, G., Lemieux, S., Marinier, A., Meloche, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3371 · Cited by 172
PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs
Prahallad, A., Heynen, G. J. J. E., Germano, G., Willems, S. M., Evers, B., Vecchione, L., Gambino, V., Lieftink, C., Beijersbergen, R. L., Di Nicolantonio, F., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.037 · Cited by 168
“PTPN11 Loss Abrogates Growth-Factor-Driven Resistance in Melanoma BRAF mutant melanomas, in general, have a favorable response to BRAF inhibition, since they mostly lack EGFR expression (Prahallad et al., 2012; Sun et al., 2014b).”
InfluentialSelf-citationYe, Q., Cai, W., Zheng, Y., Evers, B. M., & She, Q.-B. (2014) · Oncogene · doi:10.1038/onc.2013.122 · Cited by 163
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Liu, C., Lu, H., Wang, H., Loo, A., Zhang, X., Yang, G., Kowal, C., Delach, S., Wang, Y., Goldoni, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2718 · Cited by 167
“A common mechanism driving this intrinsic resistance was thought to be the EGFR-mediated feedback reactivation of the MAPK pathway as reported in preclinical colorectal cancer models (28).”
ResultMechanisms of Acquired Resistance to Targeted Cancer Therapies
Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 164
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
Elez, E., Yoshino, T., Shen, L., Lonardi, S., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2501912 · Cited by 166
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
Metadata
- Authors
- Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of Turin (IT)
- IFOM (IT)
- Corresponding author
- Bernards, René
- ORCID
- Venue
- Nature
- Published
- 2012-01-26
- Volume
- 483
- Issue
- 7387
- Pages
- 100-103
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2014881369
- Semantic Scholar
- 10564d8dc4a3ddb05a84b5a3ca8b7b622c5c17ea
- Cited by
- 2,051
- References
- 22
- Citations by year
- 2026: 75 · 2025: 81 · 2024: 106 · 2023: 145 · 2022: 126 · 2021: 168 · 2020: 145 · 2019: 117 · 2018: 139 · 2017: 129 · 2016: 149 · 2015: 215 · 2014: 188 · 2013: 172 · 2012: 91
- FWCI
- 105.49
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- European Commission (259015)
- Ministero della Salute
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- KWF Kankerbestrijding
- Associazione Italiana per la Ricerca sul Cancro (5 x mille)
- Regione Piemonte
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- BRAF V600E mutation, colon cancer, EGFR, vemurafenib, drug resistance, feedback activation, cetuximab, gefitinib, erlotinib, combination therapy, RNAi screen, melanoma, targeted therapy
- MeSH terms
- Cetuximab, Erlotinib Hydrochloride, Gefitinib, Vemurafenib, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Drug Synergism, Enzyme Activation, Female, Humans, Indoles, Melanoma, Quinazolines, Sulfonamides, Colorectal Neoplasms, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Feedback, Physiological, RNA Interference, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, HEK293 Cells, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.